Krilogy Financial LLC Raises Stock Holdings in Eli Lilly and Company $LLY

Krilogy Financial LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 35.8% during the 1st quarter, Holdings Channel.com reports. The firm owned 6,879 shares of the company’s stock after buying an additional 1,814 shares during the quarter. Krilogy Financial LLC’s holdings in Eli Lilly and Company were worth $6,218,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of LLY. Andina Capital Management LLC grew its position in shares of Eli Lilly and Company by 72.1% in the 1st quarter. Andina Capital Management LLC now owns 456 shares of the company’s stock worth $419,000 after buying an additional 191 shares during the last quarter. WealthBridge Capital Management LLC lifted its position in Eli Lilly and Company by 0.4% during the first quarter. WealthBridge Capital Management LLC now owns 5,605 shares of the company’s stock valued at $5,155,000 after acquiring an additional 25 shares during the last quarter. Total Clarity Wealth Management Inc. boosted its stake in Eli Lilly and Company by 6.3% in the first quarter. Total Clarity Wealth Management Inc. now owns 943 shares of the company’s stock valued at $868,000 after acquiring an additional 56 shares in the last quarter. Signal Advisors Wealth LLC grew its holdings in Eli Lilly and Company by 37.0% in the first quarter. Signal Advisors Wealth LLC now owns 8,544 shares of the company’s stock worth $7,858,000 after purchasing an additional 2,309 shares during the last quarter. Finally, Sovereign Financial Group Inc. grew its holdings in Eli Lilly and Company by 17.1% in the first quarter. Sovereign Financial Group Inc. now owns 937 shares of the company’s stock worth $862,000 after purchasing an additional 137 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly completed its acquisition of Centessa Pharmaceuticals, strengthening its sleep-wake disorder pipeline and adding orexin-based drug development assets. Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
• Positive Sentiment: The company announced a potential $1.9 billion research collaboration with Abbisko Therapeutics, expanding its global drug-discovery efforts and pipeline optionality. Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
• Positive Sentiment: Lilly said China approval for its GLP-1 obesity/diabetes pill could come as soon as later in 2026, reinforcing expectations for another major growth driver beyond Mounjaro and Zepbound. China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
• Positive Sentiment: Management also signaled a Europe launch strategy for the obesity pill, suggesting Lilly is preparing to expand its weight-loss franchise internationally as approvals progress. Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent analyst reports. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Friday, June 5th. Wolfe Research reaffirmed an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a research report on Thursday, May 21st. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Finally, Guggenheim reissued a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,230.89.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,115.98 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company’s fifty day moving average price is $1,026.17 and its 200-day moving average price is $1,018.81. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,182.73. The firm has a market capitalization of $1.05 trillion, a PE ratio of 39.64, a price-to-earnings-growth ratio of 1.21 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the business posted $3.34 EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.